Clinical Trial Update: A Study of RO5186582 in Down Syndrome Among Children 6 to 11 Years of Age [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating RO5186582 for Down syndrome in children aged 6 to 11 was terminated. No results are provided in the available snippet.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Down Syndrome

Drugs mentioned

• RO5186582

Snippet

Sponsor: Hoffmann-La Roche | Conditions: Down Syndrome | Phase 2 | Status: TERMINATED